Driven by excellence, focused on strategies for the longer term.

This is the crux of who we are. It is an articulation of precision in purpose, from the Firm’s beginnings to where we are today. Our collective eye is unerringly trained on tomorrow.

Deep sectoral expertise across services and industries.

Our insistence on strategic advisory exacts an in-depth understanding of and involvement with our clients’ businesses and industries. We engage not just individual businesses, but also contribute to the country’s legal and regulatory frameworks.

Personal commitment supported by experience and grit.

We commit early. We pull together internally for greater support. Every effort is sincere, every individual deeply dedicated to their task, their role, to the Firm.

Our undertakings for long-term impact are an organic extension of our purpose.

They are to employ our deep knowledge of the law beyond the business, the transaction, the deal. To use the opportunities and skills we possess, to reflect on the culture we’re creating. Individually and collectively, these are our efforts to help shape the thinking of our future generations, and arm them with strategies for true, sustainable growth.

Knowledge-sharing is intrinsic to equity and inclusivity.

This is a repository of thought leadership, deep insights and strong viewpoints, legal and other news and events and how they impact the industry and our clients.

Relevance is critical to growth. It necessitates a firm that is dynamic and responsive.

Amplifying intrinsic talent, sharpening skills, expanding knowledge, is vital to leading. It defines every aspect of how our firm functions and transacts. This is how we create new benchmarks and set industry standards.

  • Connect
May 09, 2025

SCHOTT Pharma in connection with TPG Scion Unit Trust’s acquisition of 35% stake in SCHOTT Poonawala Private Limited.

AZB & Partners is acting for SCHOTT Pharma in connection with TPG Scion Unit Trust’s acquisition of 35% stake in SCHOTT Poonawala Private Limited (“SCHOTT Poonawala”) from Serum Institute of India Private Limited (“SII”). SCHOTT Poonawalla Pvt Ltd is a joint venture of SCHOTT Pharma and SII, which is part of the Cyrus Poonawalla Group.

Our AZB deal team comprises of our Senior Partner Daksh Trivedi, Partner Aman Jain and Associates Sarthak Sharma and Srishti Kaushal, and on the Competition aspects by our Senior Partner Hemangini Dadwal.

AUTHORS & CONTRIBUTORS

TAGS

SHARE

Subscribe

DISCLAIMER

These are the views and opinions of the author(s) and do not necessarily reflect the views of the Firm. This article is intended for general information only and does not constitute legal or other advice and you acknowledge that there is no relationship (implied, legal or fiduciary) between you and the author/AZB. AZB does not claim that the article's content or information is accurate, correct or complete, and disclaims all liability for any loss or damage caused through error or omission.

RELATED READING

Deals

InCred Growth Partners Fund – I in a Series B fund raise by Celebal Technologies Private Limited.

May 14, 2025 | Corporate / Mergers & Acquisitions
Deals

KFin Technologies Limited on its acquisition of a 51% controlling stake.

May 13, 2025 | Corporate / Mergers & Acquisitions
Deals

Connedit Business Solutions Private Limited (owner of healthy snack brand Farmley) and its promoters in the Series C funding round.

May 13, 2025 | Venture Capital